BIV201
Refractory Ascites due to Liver Cirrhosis
Phase 2bActive
Key Facts
About BioVie
BioVie is a clinical-stage biotechnology company with a mission to unlock the science of longevity by targeting the inflammatory and metabolic roots of age-related diseases. Its core strategy is built around bezisterim (NE3107), a novel, orally-administered small molecule designed to selectively modulate neuroinflammation and improve insulin sensitivity in the brain. The company has advanced bezisterim into Phase 2/3 trials for Alzheimer's disease and Phase 2 studies for Parkinson's disease and Long COVID, while concurrently exploring its epigenetic impact on aging. A second clinical program, BIV201, is being developed for the treatment of refractory ascites due to liver cirrhosis.
View full company profile